Rigosertib as a potential therapeutic option for patients with recessive dystrophic epidermolysis bullosa squamous cell carcinoma
- PMID: 40658738
- PMCID: PMC12448953
- DOI: 10.1093/bjd/ljaf265
Rigosertib as a potential therapeutic option for patients with recessive dystrophic epidermolysis bullosa squamous cell carcinoma
Conflict of interest statement
Conflicts of interest: The authors declare they have no conflicts of interest.
Comment on
-
Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinoma.Br J Dermatol. 2025 Sep 18;193(4):758-766. doi: 10.1093/bjd/ljaf205. Br J Dermatol. 2025. PMID: 40439508 Clinical Trial.
References
-
- Laimer M, South AP, Mayr E et al. Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa associated advanced/metastatic cutaneous squamous cell carcinoma. Br J Dermatol 2025; 193:758–66. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources